Vineet Prabhu Email & Phone Number

Boston, Massachusetts, United States

Massachusetts, United States

•Serve as commercial program lead for pipeline assets through Phase 2 and LCM for in-line brands•Optimally shape target product profiles, claims, and product development plans by rigorously analyzing and understanding current and likely future market dynamics•Lead commercial due diligence for BD opportunities, both in-line and pipeline•Bring together a cross-functional team to guide indication sequencing project for key Ph1 to Ph3 assets with goal to maximize portfolio value while de-risking investments required•Influence and inform annual portfolio prioritization process by providing leadership an objectivecommercial perspective, including researched, verified, and relevant information• Collaborate with Japanese R&D colleagues to develop marketability assessments for preclinical assets going to governance for approval of IND-enabling studies, balancing knows vs. unknowns and precision vs. utility•Ensure organizational Disease Area Strategy is infused in thinking across the organization

Boston

Led development of strategic analyses and tools to drive CHAI's market shaping work in accelerating access to the best HIV diagnostic, treatment, and prevention products at affordable and sustainable prices.Worked cross-functionally and cross-culturally as a thought partner with HIV program, R&D, regulatory, supplier relations team, labs team, and 20+ country teams to establish and execute CHAI's market shaping strategies.Analyses and recommendations underpinned several landmark price and product development agreements, including TLD (15M+ patients accessing), pediatric DTG, and DRV/r.

•Experienced as project leader in diverse set of therapeutic areas including oncology, rare diseases, diabetes, cardiovascular, orthopedics, and nutraceuticals, as well as understanding perspectives of multiple stakeholders in the pharmaceutical value chain •25+ strategic consulting engagements, leading 2-4 person teams, for a range of clients from development-stage biotechs to top 5 global pharma, covering pre-clinical to commercial products including:  New Product Launch Planning (oncology, diabetes) Business Development Opportunity Identification (oncology, rare diseases, diabetes)  Oncology Sales Strategy  Market Sizing to Support IPO for Oncology Startup (cited in S1 filing) Field Business Planning Process  Market Entry Evaluation Private Equity Due Diligence

Phd, Cell Biology

Basic cancer research focused on cell division regulatory processes, as well as understanding the cellular effects of aneuploidy which is.

Ba, Biochemistry & Molecular Biology